Viewing nowWidiang Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Weedus Pharmaceuticals Co., Ltd.

MFDS item code 202102099 · Approved 2021.03.05 · Insurance code 660703910
Improvement of glycemic control in adults with type 2 diabetes
This medication helps control blood sugar levels in adults with Type 2 diabetes. It can be used in conjunction with dietary and exercise regimens or taken alone. If blood sugar control is inadequate with monotherapy, it can be combined with other diabetes medications like metformin. Additionally, it can be added when blood sugar control is still insufficient even with metformin and other medications. Special caution is required for Type 2 diabetic patients with cardiovascular diseases who have difficulty controlling blood sugar levels. Overall, this drug effectively improves blood sugar control in patients with Type 2 diabetes.
The recommended dose of this drug is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. Special populations • Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent eGFR < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the eGFR decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or who are on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this drug is not recommended in adults aged 85 years and older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be used in individuals who are allergic to the active ingredients or components of this drug. This medication should not be administered to patients with Type 1 diabetes or diabetic ketoacidosis. It is not to be used in patients with severely impaired kidney function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m2 or those with end-stage renal disease or undergoing dialysis. This medication contains lactose, so patients with genetic conditions like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medication. Patients with mildly impaired kidney function should be administered this medication with caution, and those with a glomerular filtration rate below 60 mL/min/1.73m2 should generally not start treatment. If the glomerular filtration rate drops below 45 mL/min/1.73m2 during treatment, this medication should be discontinued. In patients with mild to moderate heart failure, this medication should be used with caution, and it is not recommended for those with severe heart failure. When used in conjunction with insulin or insulin secretagogues such as sulfonylureas, the risk of hypoglycemia may increase, and dosage adjustments may be necessary. While taking this medication, be aware of the potential for side effects such as hypoglycemia, genital infections, increased urination, urinary tract infections, reduced fluid volume, and elevated serum creatinine. There is a risk of serious metabolic acidosis known as ketoacidosis, so if symptoms such as vomiting, abdominal pain, or difficulty breathing appear, consult healthcare professionals immediately. Elderly patients or those at risk of fluid volume loss should be cautious regarding dehydration and blood pressure drops, and it is important to monitor fluid status regularly. This medication may increase the risk of urinary and genital infections, so prompt treatment is necessary if infectious symptoms arise. Be cautious of the risk of hypoglycemia while driving or operating machinery. Women who are pregnant or planning to become pregnant should refrain from taking this medication, and breastfeeding mothers are also advised to discontinue breastfeeding. Pediatric and adolescent patients should not use this medication, as its safety and efficacy have not been established in this population. No specific toxic symptoms have been reported in cases of overdose, but if symptoms occur, immediate medical attention should be sought for appropriate treatment. This medication should be stored out of reach of children and not transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air and moisture, and it is important to keep it at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a long time.
Light yellow, biconvex, round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Weedus Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.